🍔 Weight Loss % vs Fibrosis Regression Curve Simulator

Baseline MASLD/MASH — Fat, Inflammation, Fibrosis Coexist

Untreated liver disease layers three problems at once.

• ~32%: Global MASLD prevalence (of adults worldwide)
• ~20–30%: Progress to MASH (of MASLD cases)
• ~20%: Advanced fibrosis risk (of MASH patients)
• 5–10%: Weight loss needed (to reverse disease)

Steatosis — the fat load

Triglycerides accumulate inside more than 5% of hepatocytes.

Steatohepatitis — active injury

Fat plus ballooning and lobular inflammation define MASH.

Fibrosis — the scarring stage

Stellate cells lay collagen, stiffening the liver over years.

5% Weight Loss — Steatosis Starts Clearing

Even modest weight loss mobilizes hepatic fat quickly.

• ~60%: Steatosis improvement (of patients respond)
• Lipolysis: Fat loss mechanism (reduced hepatic lipogenesis)
• ~20%: MASH resolution at 5% (still limited)
• Minimal: Fibrosis change at 5% (threshold not yet reached)

Why fat responds first

Triglyceride droplets mobilize faster than scar collagen.

Caloric deficit drives it

Any sustained energy deficit shrinks the hepatic fat pool.

Inflammation lags behind

Cellular injury markers fall more slowly than fat content.

7% Weight Loss — Steatohepatitis Resolves

Crossing 7% flips inflammation resolution odds sharply upward.

• ~65%: MASH resolution at 7% (of treated patients)
• Marked: Ballooning reduction (hepatocyte injury falls)
• ~20%: Fibrosis regression at 7% (begins appearing)
• Vilar-Gomez: Reference trial (2015 cohort study)

A histologic tipping point

Inflammation resolution rises steeply past 7% loss.

Lobular inflammation clears

Immune infiltrate density drops with sustained deficit.

Fibrosis starts to follow

Some early-stage scarring begins reversing here too.

10% Weight Loss — Fibrosis Regression Achievable

At 10% loss, scar tissue itself starts regressing.

• ~45%: Fibrosis regression at 10% (of patients improve)
• ~90%: MASH resolution at 10% (near-universal response)
• Yes: Stellate cell reversal (collagen deposition slows)
• ≥1 stage: NASH CRN stage drop (typical improvement)

Collagen turnover shifts

Degradation finally outpaces new collagen deposition.

Stellate cells quiesce

Activated fibrogenic cells revert to a resting state.

Biopsy-confirmed benefit

Paired biopsies show measurable fibrosis stage drop.

Sustained Weight Loss — Gains Hold Over Time

Durability, not just magnitude, determines lasting benefit.

• ≥12 mo: Maintenance needed (for durable regression)
• High: Regain relapse risk (without maintenance)
• Sustained: Long-term fibrosis benefit (with kept weight loss)
• Improved: Cardiometabolic bonus (lipids, glucose, BP)

Time consolidates histology

Longer maintenance locks in fibrosis regression gains.

Weight regain reverses gains

Losing the benefit is as fast as losing the weight.

Lifestyle plus pharmacotherapy

GLP-1 agents help patients sustain the needed loss.